British scientists have suggested that the current two-dose shingles vaccine appears to significantly lower the risk of heart attack and stroke, and might help to prevent thousands of deaths each year, reports The Guardian.
The research, based on records of 70 000 people in the US, found that those who had received the Shingrix jab had a 12% lower risk of a cardiovascular diagnosis in the subsequent three and a half years.
If confirmed, this benefit would be comparable to taking a daily blood pressure-lowering medication, the scientists said.
Dr Maxime Taquet, a clinical lecturer at the University of Oxford, who led the study, said: “If these results are confirmed in clinical trials, vaccinating older adults against shingles could prevent hundreds of thousands of coronary heart diseases, strokes and cases of heart failure worldwide, making it one of the most impactful interventions we could offer to protect both the brain and the heart in later life.
“The effect might be enormous.”
Shingles is a painful and serious condition caused by reactivation of the chickenpox virus, which remains dormant in the body after an earlier infection. It can cause a rash and nerve pain that may persist for months or years after the rash clears, a complication known as post-herpetic neuralgia.
The first vaccine against shingles, Zostavax, was made available in 2006 and was based on a weakened version of the chickenpox virus. This was succeeded by a more effective vaccine, Shingrix, which uses newer vaccine technology and which in the UK is offered to everyone over 65.
Several previous studies have suggested that vaccinated people may have a lower risk of cardiovascular disease. However, these studies compared vaccinated and unvaccinated people, leaving the results open to distortion.
The new study got around this by comparing the incidence of cardiovascular disease in people who were vaccinated before and after the rapid switch from Zostavax to Shingrix in the US in 2017.
The researchers tracked health records of 70 000 adults aged 60 and over for seven years after vaccination, which involved an initial dose and a booster.
Shingrix was associated with a 12% reduction in cardiovascular events – including heart attacks, heart failure and stroke – in the first three and a half years after vaccination.
By the end of the follow-up, the vaccine was associated with a 4% lower risk of cardiovascular diseases, according to the study in Nature Medicine.
While this represents a small change in absolute risk, the overall impact could be substantial, given that heart disease and stroke are leading causes of death. “If confirmed in a [randomised controlled trial], the effect of Shingrix would be equivalent to antihypertensives,” Taquet said.
Several trials are under way that could provide more definitive evidence. The scientists are also investigating why the vaccine may help to protect cardiovascular health.
One possibility is that shingles may increase the risk of heart and vascular diseases, and so the more effective vaccine reduces this risk. Alternatively, the vaccine could be having broader effects on the immune system that suppress inflammatory proteins.
Dr Hugo Pedder, a research fellow in statistical modelling at the University of Bristol who was not involved in the research, said: “A randomised trial would be the best way to confidently answer whether recombinant vaccines do provide the benefits seen here versus live vaccines, but until such a trial is done, this study provides some of the best-quality observational evidence supporting an effect of recombinant v live vaccines for cardiovascular outcomes.”
Study details
Recombinant shingles vaccination and the risk of cardiovascular events
Fabiana Corsi-Zuelli, Fang Li, Rachel Upthegrove, John Todd, Betty Raman, Paul Harrison, and Maxime Taquet.
Published in Nature Medicine on 26 August 2026
Abstract
The recombinant herpes zoster (shingles) vaccine may reduce risks of cardiovascular disease. However, existing studies have compared vaccine recipients with non-recipients and, thus, are susceptible to confounding. To mitigate these biases, we conducted a natural experiment created by the rapid transition from the live attenuated to the recombinant shingles vaccine in the United States. We compared incidences of a composite cardiovascular endpoint (ischaemic heart disease, heart failure or ischaemic stroke) among adults aged ≥60 years vaccinated immediately before versus immediately after this transition. The recombinant vaccine was associated with a 9% decrease in cardiovascular burden over 7 years (restricted mean time lost (RMTL) ratio = 0.91, 95% confidence interval (CI): 0.88−0.95). The association attenuated over time and was significant for ischaemic heart disease (10% decrease in burden; RMTL ratio = 0.90, 95% CI: 0.87−0.94) and heart failure (12% decrease in burden; RMTL ratio = 0.88, 95% CI: 0.83−0.93) in both sexes and ischaemic stroke in males (12% decrease; RMTL ratio = 0.88, 95% CI: 0.78−0.98). An association was also seen for atrial fibrillation (7% decrease in burden; RMTL = 0.93, 95% CI: 0.88−0.98) but not other cardiac, peripheral and cerebrovascular outcomes. Results were consistent in secondary analyses. These results justify clinical trials and mechanistic studies to investigate potential cardioprotective effects of shingles vaccines.
See more from MedicalBrief archives:
Shingles jab may cut heart attack, stroke risk – global review
Contracting shingles doubles stroke and heart attack risk
Shingles jab may also protect the brain, help ward off dementia